Arthritis Research
Arthritis is an inflammatory disease of the joints, including the synovium, cartilage, bone, and supporting tissues. It is the leading cause of disability in the US and there are over 100 different types of the disease. The most common types of arthritis are osteoarthritis, rheumatoid arthritis and gout.
Arthritis Research Products Targets
- Matrix Metalloprotease (16)
- Cell Adhesion Molecule (21)
- Leukotriene and Related Receptor (13)
- Others (7)
- Glucocorticoid Receptor (9)
- Focal Adhesion Kinase (4)
- Cyclooxygenases (24)
- Arthritis Research » Complement (2)
- Calcium-Sensitive Protease Modulators (12)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- p38 MAPK (16)
- Janus N-terminal Kinase (12)
- Rho-Kinases (9)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Cytokine (15)
Products for Arthritis Research - Page 15
- Cat.No. Product Name Information/Activity
-
BCC3944
A 205804
A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
-
BCC3946
A 286982
Potent inhibitor of the LFA-1/ICAM-1 interaction
-
BCC5826
Ac2-12
256447-08-2
-
BCC5825
Ac2-26
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
-
BCC3945
BIO 1211
Selective <span class='symbol'>α</span><sub>4</sub><span class='symbol'>β</span><sub>1</sub> (VLA-4) inhibitor
-
BCC8002
BIO 5192
327613-57-0
-
BCC3942
Cilengitide
Cilengitide, a cyclic RGD-containing peptide, is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50s of 4 and 79 nM, respectively.
-
BCC5988
Echistatin, α1 isoform
154303-05-6
-
BCC6998
GR 144053 trihydrochloride
1215333-48-4
-
BCC5938
KF 38789
257292-29-8


